ISPOR - Secukinumab vs Adalimumab for The Treatment of Psoriatic Arthritis- A Cost Per Responder Analysis At 48 Weeks from A Chilean Perspective

Full Text

Secukinumab vs Adalimumab for The Treatment of Psoriatic Arthritis- A Cost Per Responder Analysis At 48 Weeks from A Chilean Perspective

Abstract

Authors

R Rojas M Barbeau SM Jugl A MacPherson

Back to Volume 20, Issue 9

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now